Piramal Pharma Limited has officially notified stock exchanges about the availability of its Q4FY26 financial results conference call transcript, ensuring continued compliance with SEBI listing regulations. The pharmaceutical company filed the updated notification with BSE and NSE following the transcript release on April 30, 2026.

Latest Regulatory Compliance Filing

The company submitted an official letter to both BSE Limited and National Stock Exchange of India Limited on April 30, 2026, confirming the availability of the conference call transcript. This filing was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in continuation of their earlier letter dated April 17, 2026.

Conference Call Documentation Access

Both the audio recording and transcript of the conference call discussing audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026, are now accessible on the company's official website. Stakeholders can access both documents at piramalpharma.com/financial-reports section.

Company Leadership and Authorization

The latest regulatory filing was digitally signed by Maneesh Sharma, Company Secretary of Piramal Pharma Limited. The digital signature was authenticated on April 30, 2026, at 14:31:29 +05'30', ensuring the authenticity and legal validity of the submission.

Corporate Information

Piramal Pharma Limited operates under CIN: L24297MH2020PLC338592 with its registered office located at Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India. The company maintains transparency through regular investor communications and compliance with all regulatory requirements.

This comprehensive documentation demonstrates the company's commitment to maintaining transparency and adhering to regulatory frameworks while keeping stakeholders informed about financial performance and corporate developments through multiple accessible formats.

Piramal Pharma has received a Buy rating from Jefferies with a target price of ₹190, despite the brokerage cutting EBITDA estimates by 8-21% for FY27-28. The pharmaceutical company's operational performance remained in line with expectations, supported by strong CDMO order momentum and comprehensive FY27 growth guidance.

Jefferies Rating and Revised Estimates

Jefferies has maintained its positive outlook on Piramal Pharma while adjusting financial projections to reflect current market conditions. The brokerage's analysis highlights the impact of destocking from a patented project on near-term estimates.

FY27 Financial Guidance and Projections

The company has provided detailed financial expectations for the upcoming fiscal year, emphasizing H2-weighted revenue delivery patterns. Management anticipates momentum building from Q2, driven by CDMO order delivery schedules and Kenalog integration benefits.

Strategic ADC Investment and Market Positioning

Piramal Pharma continues its $90 million investment to expand sterile injectables and payload linker capabilities at Lexington and Riverview sites. The company positions conjugation services as the primary revenue driver and key differentiator, anchoring CDMO selection over mAb providers in the competitive ADC market.

CDMO Momentum and Operational Challenges

Despite strong CDMO order momentum supporting the company's growth trajectory, Piramal Pharma faces headwinds from destocking impact related to a patented project. This factor has influenced Jefferies' decision to reduce EBITDA estimates while maintaining confidence in the company's medium-term prospects and ADC growth strategy.